Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

ProSkelia

2002 FOUNDED
M&A STATUS
61-70 EMPLOYEES
M&A LATEST DEAL TYPE
3 FINANCING ROUNDS
Description

Provider of drug discovery and development intended to treat bone diseases. The company's portfolio of technology includes an exclusive program named oestradiol glucoside ("E2G"), which completed a Phase IIa clinical study for the treatment of menopausal symptoms, along with drugs related to the preclinical development and in vivo pharmacology.

Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Drug Discovery
Biotechnology
Primary Office
  • 102 route de Noisy
  • 93230 Romainville
  • France

ProSkelia Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore ProSkelia‘s full profile, request access.

Request full access to PitchBook

ProSkelia Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore ProSkelia‘s full profile, request access.

Request full access to PitchBook